{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:18:45Z","timestamp":1795011525296,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Refractory vasodilatory shock is a state of uncontrolled vasodilation associated with underlying inflammation and endothelial dysregulation. Rescue therapy for vasoplegia refractory to catecholamines includes methylene blue (MB) which restores vascular tone. We hypothesized that (1) at least 40% of critically ill patients would respond positively to MB administration and (2) that those who responded to MB would have a survival benefit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a retrospective review that included all adult patients admitted to an intensive care unit treated with MB for the indication of refractory vasodilatory shock. Responders to MB were identified as those with a \u2265 10% increase in mean arterial pressure (MAP) within the first 1-2 hours after administration. We examined the association of mortality to the groups of responders versus non-responders to MB. A subgroup analysis in patients undergoing continuous renal replacement therapy (CRRT) was also performed.<\/jats:p>\n                <jats:p>Statistical calculations were performed in Microsoft Excel\u00ae (Redmond, WA, USA). Where appropriate, the comparison of averages and standard deviations of demographics, dosing, MAP, and reductions in vasopressor dosing were performed via Chi squared, Fisher's exact test, or two-tailed t-test with a p-value &lt; 0.05 being considered as statistically significant. After using the F-test to assess for differences in variance, the proper two tailed t-test was used to compare SOFA scores among responders versus non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 223 patients were included in the responder analysis; 88 (39.5%) had a \u2265 10% increase in MAP post-MB administration that was not associated with a significant change in norepinephrine requirements between responders versus non-responders (<jats:italic>p<\/jats:italic>=0.41). There was a non-statistically significant trend (21.6% vs 14.8%, <jats:italic>p<\/jats:italic>=0.19) toward improved survival to hospital discharge in the MB responder group compared to the non-responder group. In 70 patients undergoing CRRT, there were 33 responders who were more likely to survive than those who were not (<jats:italic>p<\/jats:italic> = 0.0111).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with refractory shock receiving MB, there is a non-statistically significant trend toward improved outcomes in responders based on a MAP increase &gt;10%. Patients supported with CRRT who were identified as responders had decreased ICU mortality compared to non-responders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-022-01739-w","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T04:02:38Z","timestamp":1656302558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"Emily E.","family":"Naoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Dalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-7213","authenticated-orcid":false,"given":"Jamel","family":"Ortoleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"1739_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcrc.2020.02.011","volume":"57","author":"S Tchen","year":"2020","unstructured":"Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020;57:148\u201356.","journal-title":"J Crit Care."},{"issue":"2","key":"1739_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.chest.2017.12.021","volume":"154","author":"JC Jentzer","year":"2018","unstructured":"Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of refractory vasodilatory shock. Chest. 2018;154(2):416\u201326.","journal-title":"Chest"},{"issue":"9","key":"1739_CR3","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1007\/s12325-020-01422-x","volume":"37","author":"F Puntillo","year":"2020","unstructured":"Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther. 2020;37(9):3692\u2013706.","journal-title":"Adv Ther"},{"issue":"5","key":"1739_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419\u201330.","journal-title":"N Engl J Med"},{"issue":"5","key":"1739_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.jvca.2018.11.025","volume":"33","author":"JP Ortoleva","year":"2019","unstructured":"Ortoleva JP, Cobey FC. A systematic approach to the treatment of vasoplegia based on recent advances in pharmacotherapy. J Cardiothorac Vasc Anesth. 2019;33(5):1310\u20134.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"1739_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1053\/j.jvca.2018.08.017","volume":"33","author":"AD Shapeton","year":"2019","unstructured":"Shapeton AD, Mahmood F, Ortoleva JP. Hydroxocobalamin for the treatment of vasoplegia: a review of current literature and considerations for use. J Cardiothorac Vasc Anesth. 2019;33(4):894\u2013901.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"1739_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1213\/ANE.0000000000001045","volume":"122","author":"L Hosseinian","year":"2016","unstructured":"Hosseinian L, Weiner M, Levin MA, Fischer GW. Methylene blue: magic bullet for vasoplegia? Anesth Analg. 2016;122(1):194\u2013201.","journal-title":"Anesth Analg"},{"issue":"2","key":"1739_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/aca.ACA_237_16","volume":"20","author":"M Mazzeffi","year":"2017","unstructured":"Mazzeffi M, Hammer B, Chen E, Caridi-Scheible M, Ramsay J, Paciullo C. Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: a cohort study. Ann Card Anaesth. 2017;20(2):178\u201381.","journal-title":"Ann Card Anaesth"},{"issue":"1","key":"1739_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0022-5223(99)70161-3","volume":"118","author":"P Yiu","year":"1999","unstructured":"Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 1999;118(1):195\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"1739_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/0885066606290671","volume":"21","author":"ES Kwok","year":"2006","unstructured":"Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med. 2006;21(6):359\u201363.","journal-title":"J Intensive Care Med"},{"issue":"6","key":"1739_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/0310057X0203000606","volume":"30","author":"D Memis","year":"2002","unstructured":"Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002;30(6):755\u201362.","journal-title":"Anaesth Intensive Care."},{"issue":"10","key":"1739_CR12","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/00003246-200110000-00002","volume":"29","author":"MY Kirov","year":"2001","unstructured":"Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbj\u00f8rnsson B, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001;29(10):1860\u20137.","journal-title":"Crit Care Med."},{"issue":"10","key":"1739_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1097\/00003246-200210000-00015","volume":"30","author":"A Donati","year":"2002","unstructured":"Donati A, Conti G, Loggi S, M\u00fcnch C, Coltrinari R, Pelaia P, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 2002;30(10):2271\u20137.","journal-title":"Crit Care Med."},{"key":"1739_CR14","doi-asserted-by":"crossref","unstructured":"Weingartner R, Oliveira E, Oliveira ES, Sant\u2019Anna UL, Oliveira RP, Azambuja LA, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999;32(12):1505\u201313.","DOI":"10.1590\/S0100-879X1999001200009"},{"issue":"4","key":"1739_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0883-9441(98)90001-6","volume":"13","author":"M Andresen","year":"1998","unstructured":"Andresen M, Dougnac A, D\u00edaz O, Hern\u00e1ndez G, Castillo L, Bugedo G, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care. 1998;13(4):164\u20138.","journal-title":"J Crit Care."},{"issue":"12","key":"1739_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/BF01700666","volume":"21","author":"B Gachot","year":"1995","unstructured":"Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21(12):1027\u201331.","journal-title":"Intensive Care Med."},{"issue":"2","key":"1739_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3904\/kjim.2005.20.2.123","volume":"20","author":"BK Park","year":"2005","unstructured":"Park BK, Shim TS, Lim CM, Lee SD, Kim WS, Kim DS, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005;20(2):123\u20138.","journal-title":"Korean J Intern Med."},{"issue":"2","key":"1739_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00003246-199502000-00010","volume":"23","author":"JC Preiser","year":"1995","unstructured":"Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23(2):259\u201364.","journal-title":"Crit Care Med."},{"issue":"1","key":"1739_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.CCM.0000105118.66983.19","volume":"32","author":"J Bakker","year":"2004","unstructured":"Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004;32(1):1\u201312.","journal-title":"Crit Care Med"},{"issue":"1","key":"1739_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","volume":"32","author":"A L\u00f3pez","year":"2004","unstructured":"L\u00f3pez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21\u201330.","journal-title":"Crit Care Med."},{"issue":"1","key":"1739_CR21","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41598-020-58828-4","volume":"10","author":"M Porizka","year":"2020","unstructured":"Porizka M, Kopecky P, Dvorakova H, Kunstyr J, Lips M, Michalek P, et al. Methylene blue administration in patients with refractory distributive shock - a retrospective study. Sci Rep. 2020;10(1):1828.","journal-title":"Sci Rep."},{"key":"1739_CR22","doi-asserted-by":"crossref","unstructured":"Ortoleva J, Roberts RJ, Devine LT, French A, Kawabori M, Chen F, Shelton K, Dalia AA. Methylene Blue for vasoplegia during extracorporeal membrane oxygenation support. J Cardiothorac Vasc Anesth. 2021;35(9):2694\u20139.","DOI":"10.1053\/j.jvca.2020.12.042"},{"issue":"5","key":"1739_CR23","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.athoracsur.2004.10.038","volume":"79","author":"E Ozal","year":"2005","unstructured":"Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, K\u00fcc\u00fckarslan N, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005;79(5):1615\u20139.","journal-title":"Ann Thorac Surg."},{"issue":"1","key":"1739_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1213\/01.ane.0000221261.25310.fe","volume":"103","author":"AD Maslow","year":"2006","unstructured":"Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg. 2006;103(1):2\u20138 (table of contents).","journal-title":"Anesth Analg"},{"issue":"1","key":"1739_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.athoracsur.2017.02.057","volume":"104","author":"JH Mehaffey","year":"2017","unstructured":"Mehaffey JH, Johnston LE, Hawkins RB, Charles EJ, Yarboro L, Kern JA, et al. Methylene blue for vasoplegic syndrome after cardiac operation: early administration improves survival. Ann Thorac Surg. 2017;104(1):36\u201341.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"1739_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949\u201357.","journal-title":"Crit Care Med"},{"issue":"2","key":"1739_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00134-007-0867-9","volume":"34","author":"S Heemskerk","year":"2008","unstructured":"Heemskerk S, van Haren FM, Foudraine NA, Peters WH, van der Hoeven JG, Russel FG, et al. Short-term beneficial effects of methylene blue on kidney damage in septic shock patients. Intensive Care Med. 2008;34(2):350\u20134.","journal-title":"Intensive Care Med"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-022-01739-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-022-01739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T04:04:38Z","timestamp":1656302678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-022-01739-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1186\/s12871-022-01739-w","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board (Protocol #2020P000892), at Massachusetts General Hospital (Boston, MA, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Ortoleva has received a one time honoraria from La Jolla Pharmaceutical for participating in a one time expert advisory panel on the use of angiotensin II in cardiovascular surgery patients. There are no other declarations of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}